A Community‐Based Multicenter Trial of Pharmacokinetically Guided 5‐Fluorouracil Dosing for Personalized Colorectal Cancer Therapy. (12th August 2014)

• Record Type: Journal Article
• Authors: Patel, Jai N.; O'Neil, Bert H.; Deal, Allison M.; Ibrahim, Joseph G.; Sherrill, Gary B.; Olajide, Oludamilola A.; Atluri, Prashanti M.; Inzerillo, John J.; Chay, Christopher H.; McLeod, Howard L.; Walko, Christine M.
• Is Part Of: Oncologist. Volume 19:Number 9(2014)
• Page Start: 959
• Page End: 965
• Publication Date: 2014-08-12
• Subjects: Fluorouracil -- Pharmacokinetic -- Dosing -- Colorectal -- Community -- Personalized; Oncology -- Periodicals; Tumors -- Periodicals; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Oncology; Tumors; Neoplasms; Electronic journals; Periodicals; Periodicals; 616.994
• DOI: 10.1634/theoncologist.2014-0132
• Languages: English
• ISSNs: 1083-7159

Abstract

Abstract : Background: Pharmacokinetically guided (PK‐guided) versus body surface area‐based 5‐fluorouracil (5‐FU) dosing results in higher response rates and better tolerability. A paucity of data exists on PK‐guided 5‐FU dosing in the community setting. Patients and Methods: Seventy colorectal cancer patients, from one academic and five community cancer centers, received the mFOLFOX6 regimen (5‐FU 2, 400 mg/m 2 over 46 hours every 2 weeks) with or without bevacizumab at cycle 1. The 5‐FU continuous‐infusion dose was adjusted for cycles 2–4 using a PK‐guided algorithm to achieve a literature‐based target area under the concentration‐time curve (AUC). The primary objective was to demonstrate that PK‐guided 5‐FU dosing improves the ability to achieve a target AUC within four cycles of therapy. The secondary objective was to demonstrate reduced incidence of 5‐FU‐related toxicities. Results: At cycles 1 and 4, 27.7% and 46.8% of patients achieved the target AUC (20–25 mg × hour/L), respectively (odds ratio [OR]: 2.20; p = .046). Significantly more patients were within range at cycle 4 compared with a literature rate of 20% ( p < .0001). Patients had significantly higher odds of not being underdosed at cycle 4 versus cycle 1 (OR: 2.29; p = .037). The odds of a patient being within range increased by 30% at each subsequent cycle (OR: 1.30; p = .03). Less grade 3/4 mucositis and diarrhea were observed compared with historical data (1.9% vs 16% and 5.6% vs 12%, respectively); however, rates of grade 3/4 neutropenia were similar (33% vs 25%–50%). Conclusion: PK‐guided 5‐FU dosing resulted in significantly fewer underdosed patients and less gastrointestinal toxicity and allows for the application of personalized colorectal cancer therapy in the community setting. Abstract : A paucity of data exists on pharmacokinetically guided 5 fluorouracil (5‐FU) dosing in the community setting. This multicenter study demonstrated the practicality of using a simple methodology to guide 5‐FU dosing in the community setting and resulted in significantly fewer underdosed patients and less gastrointestinal toxicity.